 |
Functional Genomics & Systems Biology towards targeted Therapies
DKFZ
September 29-October 1
Heidelberg, Germany
Wednesday, September 28
12-12:10:
Introduction
Pete Honkanen, President & CEO
Aushon BioSystems
Billerica, MA, USA
12:10 – 12:45:
“The Reverse-Phase Protein Microarray Platform:
Applications in Preclinical and Clinical Studies”
Julia D. Wulfkuhle, Ph.D.
Center for Applied Proteomics and Molecular Medicine
George Mason University
Manassas, VA, USA
Presentation Abstract:
Advances in cancer treatment have generated a need to more precisely define and identify those patients who will derive the most benefit from new-targeted therapeutic agents. Cellular signaling pathways are protein-based networks most often targeted by these drugs, with the intended effect being to disrupt aberrant protein phosphorylation-based signaling activity. The Reverse-Phase Protein Microarray (RPMA) platform has tremendous potential for providing detailed information about the state of the cellular ‘circuitry’ in samples ranging from cell culture lysates to tiny core needle biopsy specimens. When combined with Laser Capture Microdissection (LCM), measurements of hundreds of specific phosphorylated proteins spanning large classes of important signaling pathways can be obtained at once from only a few thousand cells. Implementation of RPMA technology in the preclinical, research and clinical settings for profiling patient tissue specimens before, during and after therapy could provide important diagnostic and prognostic information, and could help in therapeutic decision making and monitoring response or resistance to these new targeted agents.
12:45 – 12:50: Q&A
12:50 – 1:25:
“The Institut Curie RPPA Platform Applied to Cancer Proteomics“
Dr. Leanne De Koning, Ph.D.
Laboratory of Cell Signaling
Institut Curie , Département de Transfert
Hôpital Saint-Louis 75010 Paris
Presentation Abstract:
To Come
1:25 – 1:30: Q&A
1:30 – 1:55:
“Printing and Processing Reverse-Phase Protein Lysate Microarrays”
Pete Honkanen, President & CEO
Aushon BioSystems
Billerica, MA, USA
Presentation Abstract:
“Printing and Processing Reverse-Phase Protein Lysate Microarrays”
Aushon BioSystems’ 2470 Arrayer is a proven technology for building exceptionally high quality reverse-phase protein lysate microarrays (RPAs). The 2470 can produce arrays of the often viscous lysate material with the linearity and consistency to permit data extraction from dilution series curves. This talk will describe the 2470 technology as well as give a general overview of the entire RPA process.
1:55 – 2:00: Q&A
|
 |
Speaker Bios:
Julia D. Wulfkuhle, Ph.D.
Center for Applied Proteomics and Molecular Medicine
George Mason University
Manassas, VA, USA
Read Bio »
Dr. Leanne De Koning, Ph.D
Laboratory of Cell Signaling
Institut Curie, Département de Transfert
Hôpital Saint-Louis 75010 Paris
Read Bio »
Pete Honkanen
President & CEO, Aushon BioSystems, Inc.
Aushon BioSystems
Billerica, MA, USA
Read Bio »
|
